EWING, N.J.–(BUSINESS WIRE)–

Antares Pharma, Inc. (ATRS) today announced that Eamonn P. Hobbs, President and Chief Executive Officer, will present a corporate overview at the 33^rd Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2015 at 9:00 a.m. Pacific Time.

A live webcast of the presentation will be available via the “Investor Information/Webcasts” page of the Antares website, www.antarespharma.com. A replay of the webcast will also be archived on Antares’ website for 90 days following the presentation.

About Antares Pharma

Antares Pharma focuses on self-administered parenteral pharmaceutical products. The Company markets OTREXUP™ (methotrexate) injection for subcutaneous use in the treatment of adults with severe active rheumatoid arthritis and children with active polyarticular juvenile idiopathic arthritis. LEO Pharma markets OTREXUP™ to dermatologists for adults with severe recalcitrant psoriasis. Antares Pharma is also developing QuickShot^® Testosterone for testosterone replacement therapy. The Company’s technology platforms include VIBEX^® disposable Medi-Jet, disposable multi-use pen injectors and reusable needle-free injectors. Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin^® [somatropin (rDNA origin) for injection] human growth hormone (hGH), VIBEX^® epinephrine and several other products. In the U.S. Antares has received FDA approval for Gelnique 3%™ (oxybutynin) gel, a treatment for overactive bladder that is marketed by Actavis. Elestrin^® (estradiol gel) is FDA approved for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and is marketed in the U.S. by Meda.

• Health Care Industry
• Health